A biotechnology company developing chemokine-based therapies for the treatment of cancer, blood disorders and vascular diseases, Chemokine Therapeutics (TSE: CTI) has been granted by the United States Patent and Trademark Office a U.S. Patent 7,091,310 B2. The said patent is relating to chemokine analogs for the treatment of human disease.
Covered in the said patent are chemokine analogs (peptide agonists and antagonists of chemokines) with potential treatment capabilities in various diseases and disorders, and as an adjunct treatment of the following: autoimmune diseases, acute chronic inflammation, cancer, cardiovascular disease, infectious disease and inflammatory disorders (rheumatoid arthritis, chronic inflammatory bowel disease) chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, atherosclerosis, psoriasis, rhinitis, autoimmunity and organ transplant rejection.
Dr. Hassan Salari, President and Chief Executive Officer of Chemokine Therapeutics, stated:
"This new patent grant reinforces our overriding strategy to broaden the proprietary scope of our drug development platform while helping to further solidify our intellectual property position."
Chemokines, a class of signaling proteins, play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection and stem cells, including tissue repair and regeneration. Chemokines also plays an important role in cancer metastasis and growth.
Read the full press release.
Comment Preview